Articles tagged "FK506"

2018 American Transplant Congress
Long-Term Effects of Ketoconazole in Rapid Tacrolimus Metabolizers Post-Renal Transplantation
J. Ching,¹ S. Anders,¹ M. Janusek,¹ L. Hutchinson,¹ A. Freeman,¹ U. Patel,¹ A. Mohammed,⁴ H. Bohorquez.^2,3
¹Department of Pharmacy, Ochsner Clinical Foundation, New Orleans, LA; ²Multi-Organ Transplant Institute, Ochsner Clinical Foundation, New Orleans, LA; ³The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA; ⁴Academic Center, Ochsner Clinical Foundation, New Orleans, LA.
Introduction: Genetic polymorphisms in cytochrome P-450 enzymes can cause variations in tacrolimus (tac) metabolism. Ketoconazole (keto), a potent CYP450 and P-glycoprotein inhibitor, can be used…
2018 American Transplant Congress
Time within Therapeutic Range: A Comparison of Three Tacrolimus Formulations in Renal Transplant Recipients
K. Khalil, P. West-Thielke, A. Lichvar, E. Benedetti, S. Patel.
University of Illinois Hospital & Health Sciences System, Chicago, IL.
Purpose: To compare three formulations of tacrolimus (TAC) and assess differences in time within therapeutic range (TTR) and variability in levels.Methods: Renal transplant recipients from…
2018 American Transplant Congress
Evaluation of Tacrolimus Extended-Release in African American Renal Transplant Recipients
T. Sparkes, B. Ravichandran, C. Williams, B. Thomas, B. Masters.
University of Maryland, Baltimore.
Purpose: Limited data exists to guide appropriate dosing strategies for novel tacrolimus formulations, such as tacrolimus XL (Astagraf XL). This is especially true in the…
2018 American Transplant Congress
Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients- 3 Years Follow-Up
S. Narumi,¹ Y. Watarai,¹ N. Goto,² T. Hiramitsu,¹ M. Tsujita,² M. Okada,¹ K. Futamura,² T. Kobayashi.³
¹Transplant Surgery, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Aichi, Japan; ²Transplant Nephrology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Aichi, Japan; ³Kidney Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…
2018 American Transplant Congress
Clinical Significance of Tacrolimus Trough Level at the Early Period after Kidney Transplantation
W. Park,^1,2 S. Yeo,¹ S. Kang,^1,2 H. Park,¹ K. Jin,^1,2 S. Park,^1,2 S. Han.^1,2
¹Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea; ²Keimyung University Kidney Institute, Daegu, Republic of Korea.
Background:The stable immunosuppressant level at the early period after kidney transplantation (KT) is one of the most important factors to decide the prognosis of KT.…
2018 American Transplant Congress
Tacrolimus and Isavuconazole Therapy: What about the Drug Interaction?
C. Gill,¹ N. Mercuro,¹ R. Kenney,¹ A. Jantz,¹ B. Summers,¹ N. Sulejmani,¹ S. Davis.^1,2
¹Henry Ford Hospital, Detroit; ²Wayne State University, Detroit, MI.
Introduction:Isavuconazole (ISV) is a triazole antifungal that is often utilized in solid organ transplant recipients (SOTR) for the treatment of invasive aspergillosis and mucormycosis. Isavuconazole…
2018 American Transplant Congress
Target Tacrolimus Troughs and CYP3A5 Polymorphisms Do Not Predict Therapeutic Drug Exposure in African American and Caucasian Renal Transplant Recipients
K. Tornatore,^1,4 K. Attwood,² D. Brazeau,³ S. Chang,⁴ R. Venuto.⁴
¹Pharmacy, School of Pharmacy, University at Buffalo(UB), Buffalo; ²Biostatistics, RPCI, Buffalo; ³Pharmaceutical Sciences, University of New England, Portland; ⁴Nephrology, UB School of Medicine, Buffalo.
Background: African American(AA) renal transplant recipients(RTR) require larger tacrolimus(TAC) doses to achieve similar troughs to Caucasians which may be due to CYP3A5 polymorphisms. TAC pharmacokinetics…
2018 American Transplant Congress
Prevalence and Impact of CYP3A5 Genomic Variances on Clinical Outcomes among African-American Kidney Transplant Recipients
A. Maldonado,¹ S. Hudson,² L. Rebellato,² T. Asempa.¹
¹Vidant Medical Center, Greenville, NC; ²East Carolina University, Greenville, NC.
Introduction: Kidney transplantation in African American (AA) recipients continues to demonstrate inferior outcomes when compared with other race/ethnicities. Contributing factors encompass differences in pharmacogenomics, and…
2018 American Transplant Congress
Long-Term Outcomes of Liver Transplantation in Patients with Pre-Transplant Renal Dysfunction Treated with Induction Therapy and Delayed Reduced De Novo Once-Daily Tacrolimus
M. Gastaca,¹ J. Bustamante,² A. Ventoso,¹ J. Fernandez,² P. Ruiz,¹ M. Testillano,² M. Prieto,¹ P. Salvador,² I. Palomares,¹ M. Senosiain,² M. Suarez,² A. Valdivieso.¹
¹Hepatobiliary Surgery and Liver Transplant Unit, Cruces University Hospital, Bilbao, Spain; ²Hepatology Unit, Cruces University Hospital, Bilbao, Spain.
AIM: To describe the long-term outcome of liver transplantation (LT) in patients with pre-transplant renal dysfunction treated with induction therapy and delayed reduced de novo…
2018 American Transplant Congress
Tacrolimus Exposure in Human Proximal Tubule Cells Results in Differentially Increased CTGF Expression in Relation to Pharmacogenetic Variants of CYP3A5 and ABCB1
N. Knops,¹ Y. Ramazani,² B. Van den Heuvel,² R. Goldschmeding,³ T. Nguyen,³ E. Levtchenko,¹ D. Kuypers.⁴
¹Paediatric Nephrology and Solid Organ Transplantation, University Hospitals Leuven, Leuven, Belgium; ²Laboratory of Paediatrics, KU Leuven, Leuven, Belgium; ³Pathology, University Medical Center Utrecht, Utrecht, Netherlands; ⁴Nephrology, University Hospitals Leuven, Leuven, Belgium.
AIM: Clinical studies have demonstrated the importance of genetic variation for tacrolimus disposition and suggested a role in the development of renal fibrosis associated with…